Dr. Dean G. Tsarwhas, MD

Years In Practice

19

Gender

Male

Field of Medicine

• Hematology Oncology (Cancer)

Specialty

• Hematology Oncology (Cancer)

Clinical Interests

• Biologic Therapy
• Breast Cancer
• Chemotherapy
• Clinical Trials
• Colon Cancer
• Gastrointestinal Malignancies
• Hematology
• Lung Cancer
• Non-Hodgkin's Lymphoma
• Prostate Cancer

Practice Information

Name

North Shore Oncology Hematology Associates

Web Site

http://northshoreoncology.com

Education and Training

Medical School

Northeastern Ohio Universities College of Medicine

Internship

The University of Michigan Medical Center

Residency

The University of Michigan Medical Center

Fellowship

Dana-Farber Cancer Institute, Harvard Medical School

1991 - 1993

Fellowship Dana Farber Cancer Institute, Harvard Medical School

1990 - 1991

Chief Medical Resident, The University of Michigan Medical Center

1988 - 1990

Residency, The University of Michigan Medical Center

1987 - 1988

Internship, The University of Michigan Medical Center

1983 - 1987

Medical School, Northeastern Ohio Universities College of Medicine

Board Certifications

• Internal Medicine
  Medical Oncology
  

Hospital Affiliations

• Northwestern Lake Forest Hospital
  Advocate Condell Medical Center
  Advocate Good Shepherd Hospital
  Centegra Northern Illinios Medical Center
  Centegra Memorial Medical Center
  

Professional Experience

1993 - Present

Medical Oncologist, North Shore Oncology Hematology Associates

Professional Honors

• Alpha Omega Alpha Honor Medical Society
  
  Outstanding First Year House Officer, The University of Michigan Medical Center
  
  Western Reserve Care Award in Medicine

Professional Societies and Committees

Memberships

• American Society of Clinical Oncology
  American Society of Hematology
  American Medical Association
  American College of Physicians
  Illinois Medical Oncology Society

Selected Publications

• Nabhan C, Lestingi TM, Galvez A, Tolzien K, Kelby SK, Tsarwhas D, Newman S, Bitran JD. Erlotinib has moderate single agent activity in chemotherapy-naive castration-resistant prostate cancer: final results of a phase II trial. Urology 2009 Sep 74(3):665-71
  
  Ganju RK, Sunday M, Tsarwhas DG, Card A, Shipp MA. CD10/NEP in non-small cell lung carcinomas. Relationship to cellular proliferation. Journal of Clinical Investigation. 1994 November;94(5):1784-91.
  
  Anderson IC, Sugarbaker DJ, Ganju RK, Tsarwhas DG, Richards WG, Sunday M, Kobzik L, Shipp MA. Stromelysin-3 is overexpressed by stromal elements in primary non-small lung cancers and regulayed by retinoic acid in pulmonary fibroblasts. Cancer Research, 1995 vol 55 (18), 4120-4126